8-K current report · filed Nov 9, 2026

Editas Medicine, Inc. (EDIT) 8-K Current Report: November 9, 2026

Item 2.02Item EX-99.1EDIT overview

Short answer

Editas Medicine, Inc. (EDIT) filed an 8-K current report with the SEC on November 9, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Editas Medicine reported financial results for the quarter ended September 30, 2026.

Editas Medicine, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Editas Medicine reported financial results for the quarter ended September 30, 2026
  • Business highlights accompany the quarterly results in Exhibit 99.1
  • Investor-relevant figures and guidance require review of the referenced press release

Item EX-99.1 · Exhibit EX-99.1

  • Phase 1/2 Strive study approved in Australia, with EDIT-401 dosing expected in 2026 and initial safety data targeted for Q1 2027
  • EDIT-401 preclinical LDL-C reduction of ≥90% maintained over 10 months, supporting potential durability but not yet demonstrating human efficacy
  • BMS-986527 second IND/CTA acceptance triggered a milestone payment, increasing collaboration revenue to $10.4 million from $7.5 million
  • Cash, cash equivalents and marketable securities $190.2 million, supporting operations into the second half of 2028
  • Net loss narrowed to $23.4 million, or $0.15 per share, from $25.1 million, or $0.28 per share, despite higher R&D and G&A expenses

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Editas Medicine, Inc. 8-K filings

Get the next EDIT 8-K as it lands

Follow EDIT for push alerts, or ask the research agent what this filing means.